middle.news
Anteris Enrolls First US Patients in Pivotal DurAVR Heart Valve Trial
9:28am on Wednesday 6th of May, 2026 AEST
•
Healthcare
Read Story
Anteris Enrolls First US Patients in Pivotal DurAVR Heart Valve Trial
9:28am on Wednesday 6th of May, 2026 AEST
Key Points
First US patients enrolled and treated in PARADIGM trial
Randomized controlled study compares DurAVR THV to commercial TAVRs
Trial aims to enroll 1000 patients assessing mortality, stroke, hospitalisation
CMS approval enabled rapid US site activation and patient enrolment
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Anteris Technologies Global (ASX:AVR)
OPEN ARTICLE